XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 12 Months Ended
Apr. 01, 2023
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include integration and transaction costs, amortization of acquired intangible assets, restructuring and restructuring related costs, digital transformation costs related to the upgrade of our enterprise resource planning system, impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains and losses on dispositions and sale of assets. Although these amounts are excluded from
segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
(In thousands)202320222021
Net revenues
Plasma$500,489 $351,945 $333,334 
Blood Center289,365 294,541 307,370 
Hospital378,206 321,580 210,606 
Net revenues by business unit1,168,060 968,066 851,310 
Service (1)
21,424 20,811 20,758 
Effect of exchange rates(20,824)4,319 (1,605)
Net revenues$1,168,660 $993,196 $870,463 
(1) Reflects revenue for service, maintenance and parts.

(In thousands)202320222021
Segment operating income
Plasma$278,580 $183,131 $172,463 
Blood Center132,107 136,691 141,962 
Hospital154,416 129,783 84,066 
Segment operating income565,103 449,605 398,491 
  Corporate expenses (1)
(355,089)(281,476)(256,751)
  Effect of exchange rates8,419 18,993 12,830 
Amortization of acquired intangible assets(32,640)(47,414)(32,830)
Impairment of assets and PCS2 related charges616 (5,732)(25,696)
Integration and transaction costs411 (21,604)(18,421)
Restructuring and restructuring related costs(11,549)(28,824)(15,661)
Digital transformation costs(4,536)— — 
MDR and IVDR costs(9,854)(11,033)(4,130)
Litigation-related charges(5,230)(1,368)(897)
Gains on divestitures and sale of assets382 9,603 32,812 
Operating income$156,033 $80,750 $89,747 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

(In thousands)202320222021
Depreciation and amortization
Plasma$41,612 $28,314 $24,093 
Blood Center13,927 32,489 39,672 
Hospital37,768 36,944 20,522 
Total depreciation and amortization (excluding impairment charges)$93,307 $97,747 $84,287 
(In thousands)April 1,
2023		April 2,
2022
Long-lived assets(1)
Plasma$202,075 $129,241 
Blood Center68,395 82,714 
Hospital40,415 46,527 
Total long-lived assets$310,885 $258,482 
(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by operating regions is presented below:
(In thousands)April 1,
2023		April 2,
2022
Long-lived assets(1)
United States$251,812 $200,927 
Japan997 1,096 
Europe14,587 11,989 
Asia26,263 28,132 
Other17,226 16,338 
Total long-lived assets$310,885 $258,482 
(1) Long-lived assets are comprised of property, plant and equipment.

(In thousands)202320222021
United States$842,897 $639,322 $522,607 
Japan61,295 75,562 77,676 
Europe156,680 163,520 159,077 
Asia104,135 110,802 105,820 
Other3,653 3,990 5,283 
Net revenues$1,168,660 $993,196 $870,463 

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
(In thousands)202320222021
Plasma products and services563,734 427,611 414,266 
Blood Center products and services226,819 236,158 239,614 
Hospital products and services378,107 329,427 216,583 
Net revenues$1,168,660 $993,196 $870,463